Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: The ucsf experience with 149 patients

Pancreas

Volumn 41, Issue 6, 2012, Pages 840-844

  Parekh, Justin R ^a,b   Wang, Sam C ^a,b   Bergsland, Emily K ^a,b   Venook, Alan P ^a,b   Warren, Robert S ^a,b   Kim, Grace E ^a,b   Nakakura, Eric K ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

lymph nodes; neuroendocrine tumors; pancreas

Indexed keywords

ADULT; ARTICLE; CANCER SURGERY; ETHNICITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; PANCREAS RESECTION; PANCREAS TUMOR; PANCREATIC NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; TUMOR VOLUME;

ADULT; AGED; CHI-SQUARE DISTRIBUTION; DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; LOGISTIC MODELS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUROENDOCRINE TUMORS; ODDS RATIO; PANCREATECTOMY; PANCREATIC NEOPLASMS; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SAN FRANCISCO; SPLENECTOMY;

EID: 84863924208     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31823cdaa0     Document Type: Article

References (25)

1. Yao JC, Eisner MP, Leary C, et al. Population-based study of islet cell carcinoma. Ann Surg Oncol. 2007;14(12):3492Y3500.
2. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97(4):934Y959.
3. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501Y513.
4. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514Y523.
5. Pitt SC, Pitt HA, Baker MS, et al. Small pancreatic and periampullary neuroendocrine tumors: resect or enucleate? J Gastrointest Surg. 2009;13(9):1692Y1698.
6. Grant CS. Insulinoma. Best Pract Res Clin Gastroenterol. 2005;19(5):783Y798.
7. Vagefi PA, Razo O, Deshpande V, et al. Evolving patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms: the Massachusetts General Hospital experience from 1977 to 2005. Arch Surg. 2007;142(4):347Y354.
8. Bilimoria KY, Talamonti MS, Tomlinson JS, et al. Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Ann Surg. 2008;247(3):490Y500.
9. Haynes AB, Deshpande V, Ingkakul T, et al. Implications of incidentally discovered, nonfunctioning pancreatic endocrine tumors: short-term and long-term patient outcomes. Arch Surg. 2011;146(5):534Y538.
10. Jarufe NP, Coldham C, Orug T, et al. Neuroendocrine tumours of the pancreas: predictors of survival after surgical treatment. Dig Surg. 2005;22(3):157Y162.
11. Kazanjian KK, Reber HA, Hines OJ. Resection of pancreatic neuroendocrine tumors: results of 70 cases. Arch Surg. 2006;141(8):765Y769; discussion 769Y770.
12. Schurr PG, Strate T, Rese K, et al. Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: an institutional experience. Ann Surg. 2007;245(2):273Y281.
13. Bouvier AM, Haas O, Piard F, et al. How many nodes must be examined to accurately stage gastric carcinomas? Results from a population based study. Cancer. 2002;94(11):2862Y2866.
14. Slidell MB, Chang DC, Cameron JL, et al. Impact of total lymphnode count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large,population-based analysis. Ann Surg Oncol. 2008;15(1):165Y174.
15. Chu QD, Hill HC, Douglass HO Jr, et al. Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas. Ann Surg Oncol. 2002;9(9):855Y862.
16. Ferrone CR, Tang LH, Tomlinson J, et al. Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? J Clin Oncol. 2007;25(35):5609Y5615.
17. Ito H, Abramson M, Ito K, et al. Surgery and staging of pancreatic neuroendocrine tumors: a 14-year experience. J Gastrointest Surg. 2010;14(5):891Y898.
18. Gomez-Rivera F, Stewart AE, Arnoletti JP, et al. Surgical treatment of pancreatic endocrine neoplasms. Am J Surg. 2007;193(4):460Y465.
19. Olson P, Lu J, Zhang H, et al. MicroRNA dynamics in the stages f tumorigenesis correlate with hallmark capabilities of cancer.Genes Dev. 2009;23(18):2152Y2165.
20. Casadei R, Ricci C, Rega D, et al. Pancreatic endocrine tumors less than 4 cm in diameter: resect or enucleate? A single-center experience. Pancreas. 2010;39(6):825Y828.
21. Le Voyer TE, Sigurdson ER, Hanlon AL, et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol. 2003;21(15):2912Y2919.
22. Tepper JE, O'Connell MJ, Niedzwiecki D, et al. Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol. 2001;19(1):157Y163.
23. Mariette C, Piessen G, Briez N, et al. The number of metastatic lymph nodes and the ratio between metastatic and examined lymphnodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent. Ann Surg. 2008;247(2):365Y371.
24. Marchet A, Mocellin S, Ambrosi A, et al. The ratio between metastatic and examined lymph nodes (N ratio) is an independent prognostic factor in gastric cancer regardless of the type of lymphadenectomy: results from an Italian multicentric study in 1853 patients. Ann Surg. 2007;245(4):543Y552.
25. Kocher HM, Sohail M, Benjamin IS, et al. Technical limitations of lymph node mapping in pancreatic cancer. Eur J Surg Oncol. 2007;33(7):887Y891.